Table 5 Summarized replies on additional comments
From: A survey in Mexico about ethics dumping in clinical research
| # | Summarized replies |
|---|---|
| 1. | No [effective] participation of hospital directives in research committees |
| 2. | There is exploitation and harassment of vulnerable groups in companies due to the pressure to recover investments |
| 3. | Lax inclusion criteria that increase the likelihood of adverse events |
| 4. | Medical representatives use aggressive persuasion strategies |
| 5. | Research teams are paid less, patients receive less economic support for expenses and materials are of poorer quality than in HICs countries |
| 6. | Better laws for research units are needed |
| 7. | Improve regulations on post-trial information and treatment for patients |
| 8. | Authorities abuse their power |
| 9. | National registry of qualified researchers [to be started by the authorities]; presence of unqualified personnel; national registry of committee members |
| 10. | It is necessary funding of the research industry (CONACYT [National Science and Technology Council] funding is insufficient), under the guidance of health professionals. |
| 11. | Wages are lower, while the work is more difficult |
| 12. | Academic recognition for researchers |
| 13. | A handbook of research ethics procedures, regulations, social dimensions, etc. is necessary |
| 14. | Create high-performance research centers to attract investment |
| 15. | Need for quality medications at a fair price |